Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
CONCLUSIONS: The results of this economic model suggest tofacitinib is a cost-effective treatment option for patients with moderate-to-severe UC in Germany.
PMID: 33502905 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Colectomy | Economics | Germany Health | Health Insurance | Health Management | Humira | Inflammatory Bowel Disease | Insurance | Remicade | Stelara | Study | Ulcerative Colitis